Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Cancer Metastatic × patritumab deruxtecan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 8 Carcinoma, Non-Small-Cell Lung 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Neoplasms 3 Lung Neoplasms 3 Esophageal Neoplasms 3 Neoplasm Metastasis 2 Brain Neoplasms 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solid Tumor, Adult 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Nonsquamous Non-small Cell Lung Cancer 1 Non-Small Cell Lung Cancer Metastatic 1 Meningeal Neoplasms 1 Melanoma 1 Head and Neck Neoplasms 1 Gastrointestinal Neoplasms 1 Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Breast Cancer Metastatic 1

Interventions

Fulvestrant 5 Letrozole 4 exemestane 3 Capecitabine 3 Anastrozole 3 ribociclib 2 dalpiciclib 2 apatinib 2 Trastuzumab 2 Gemcitabine 2 Docetaxel 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 pyrotinib 1 patritumab deruxtecan 1 palbociclib 1 olaparib 1 nirogacestat 1 margetuximab 1 irinotecan sucrosofate 1 fluzoparib 1 abemaciclib 1 Zoledronic Acid 1 Vinorelbine 1 Tamoxifen 1 Paclitaxel 1 Neoadjuvant Therapy 1 Liposomes 1 Irinotecan 1 Ga(III)-DOTATOC 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06298084 2024-03-29

ICARUSBREAST02

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡